Evidence map›Paper›PMID 25264427›Full record

ArticleCancer cell international2014

Characterization of ductal carcinoma in situ cell lines established from breast tumor of a Singapore Chinese patient.

Jacklyn Wy Yong, Meng Ling Choong, SiFang Wang, Yu Wang, Shermaine Qy Lim, May Ann Lee

Open access · goldAbstract read
In one paragraph

Article in Cancer cell international, 2014. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
0.7field-weighted citation impact, top 23% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 19 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Review
  5. Article
  6. In Vitro Models for Studying Invasive Transitions of Ductal Carcinoma In Situ.Journal of mammary gland biology and neoplasia · 2019
    Review
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

6 authors at 2 institutions in 1 country.

Jacklyn Wy YongCell-Based Assay Development Group, Experimental Therapeutics Centre, Agency for Science Technology and Research, 31 Biopolis Way, #03-01 Nanos Building, Singapore, 138669 Singapore.
Meng Ling ChoongCell-Based Assay Development Group, Experimental Therapeutics Centre, Agency for Science Technology and Research, 31 Biopolis Way, #03-01 Nanos Building, Singapore, 138669 Singapore.
SiFang WangCell-Based Assay Development Group, Experimental Therapeutics Centre, Agency for Science Technology and Research, 31 Biopolis Way, #03-01 Nanos Building, Singapore, 138669 Singapore.
Yu WangCell-Based Assay Development Group, Experimental Therapeutics Centre, Agency for Science Technology and Research, 31 Biopolis Way, #03-01 Nanos Building, Singapore, 138669 Singapore.
Shermaine Qy LimCell-Based Assay Development Group, Experimental Therapeutics Centre, Agency for Science Technology and Research, 31 Biopolis Way, #03-01 Nanos Building, Singapore, 138669 Singapore.
May Ann LeeCell-Based Assay Development Group, Experimental Therapeutics Centre, Agency for Science Technology and Research, 31 Biopolis Way, #03-01 Nanos Building, Singapore, 138669 Singapore.
Experimental Drug Development Centre · SGAgency for Science, Technology and Research · SG

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundFive cell lines were established from a Singaporean patient of Chinese origin with breast ductal carcinoma in situ (DCIS). These five cell lines express exogenous human telomerase reverse transcriptase (hTERT) which confers the ability to proliferate indefinitely.

methodsCells were isolated from the DCIS excision and transfected with a plasmid expressing hTERT, a catalytic subunit of telomerase. Five immortalized colonies were propagated and characterized by karyotyping, array comparative genomic hybridization (CGH), immunostaining and Western blots for biomarkers, in vitro anchorage independent growth, in vivo mouse tumorigenicity, drug sensitivity, species authentication and virology safety testing.

resultsArray CGH analysis showed that the cell lines harbored different specific genetic aberrations. Common mutations observed in most breast cancer cell lines such as the general loss of heterozygosity (LOH) throughout chromosome X and chromosome 17 are also observed in our cell lines. The cell lines were further characterized as human breast cells that are estrogen- and progesterone-receptor positive, and sensitive to tamoxifen. The cell lines showed anchorage-independent growth in the soft agar assay and can grow in common culture medium without supplementation with growth factor, therefore demonstrating transformed characteristics. Four of the cell lines can engraft and form measureable tumors after 50 days when injected subcutaneously into immune-deficient (SCID) mice. The weak tumorigenicity of these cell lines corresponded well with their non-malignant growth origin. The cell lines were authenticated to be of human origin based on DNA fingerprint of the cells. The cell lines were free from contamination of 20 viruses and mycoplasma in the virological safety test panel.

conclusionsUnlike most available breast cell lines, our cell lines are derived from primary breast cancer tissues that represent earlier grades or tumor progression stages. They would be useful as study models for basic and clinical research programs directed at early diagnosis and intervention.

Indexed as

Breast cancerCell lineChineseDuctal carcinoma in situEstrogenImmortalizationProgesteroneTelomeraseTumorigenicity

Identifiers

PMID25264427
PMCPMC4177074
OpenAlexW2168088079

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.